Sugi Predict

Sugi Predict / Compounds / SCHEMBL186598

SCHEMBL186598

SCHEMBL186598

CC1(C)CNC(=O)c2cc(NC(=O)c3cccnc3Nc3ccc4cn[nH]c4c3)ccc21

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDR P35968 3/20 0.59
▸ MAP4K4 O95819 4/20 0.47
▸ FLT1 P17948 3/20 0.47
▸ FLT3 P36888 3/20 0.47
▸ EGFR P00533 2/20 0.47
▸ LCK P06239 2/20 0.47
▸ CSF1R P07333 2/20 0.47
▸ RET P07949 2/20 0.47
▸ KIT P10721 2/20 0.47
▸ FGFR1 P11362 2/20 0.47
▸ FRK P42685 2/20 0.47
▸ BLK P51451 2/20 0.47
▸ PTK6 Q13882 2/20 0.47
▸ SLK Q9H2G2 2/20 0.47
▸ MAP3K20 Q9NYL2 2/20 0.47
▸ JAK1 P23458 2/20 0.47
▸ CIT O14578 1/20 0.47
▸ MAP3K7 O43318 1/20 0.47
▸ RIPK2 O43353 1/20 0.47
▸ STK10 O94804 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3895020 0.89 KDR (0.62) KDRMAP4K4FLT1FLT3EGFR
SCHEMBL3892506 0.85 KDR (0.66) KDRMAP4K4FLT1FLT3EGFR
SCHEMBL187231 0.85 KDR (0.59) KDRMAP4K4FLT1FLT3EGFR
SCHEMBL3889735 0.84 KDR (0.62) KDRMAP4K4FLT1FLT3EGFR
SCHEMBL3903625 0.84 KDR (0.59) KDRMAP4K4FLT1FLT3EGFR
SCHEMBL3891421 0.83 KDR (0.61) KDRMAP4K4FLT1FLT3EGFR
SCHEMBL3953801 0.83 KDR (0.60) KDRMAP4K4FLT1FLT3EGFR
SCHEMBL187741 0.81 KDR (0.57) KDRMAP4K4FLT1FLT3EGFR
SCHEMBL3892855 0.80 KDR (0.61) KDRMAP4K4FLT1JAK1NPC1
SCHEMBL3891371 0.79 KDR (0.56) KDRMAP4K4FLT1FLT3EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 149 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100074909-A1 Combinations for the treatment of cancer AMGEN INC (US) 2010-03-25 — — US claimed
US-7514564-B2 Substituted amine derivatives and methods of use AMGEN INC. (US) 2009-04-07 — — US claimed
EP-1915151-A2 COMBINATIONS FOR THE TREATMENT OF CANCER COMPRISING ANTI-EGFR ANTIBODY AND VEGFR INHIBITORS Amgen, Inc (US) 2008-04-30 — — EP claimed
WO-2006102504-A2 COMBINATIONS FOR THE TREATMENT OF CANCER COMPRISING ANTI-EGFR ANTIBODY AND VEGFR INHIBITORS AMGEN INC (US) 2006-09-28 — — WO claimed
US-20060216288-A1 Combinations for the treatment of cancer AMGEN INC (US) 2006-09-28 — — US claimed
US-7105682-B2 Substituted amine derivatives and methods of use AMGEN INC. (US) 2006-09-12 — — US claimed
US-20030195230-A1 Substituted amine derivatives and methods of use AMGEN INC. 2003-10-16 — — US claimed
EP-3170824-B1 A 6-([1,2,4]TRIAZOLO[4,3-A]PYRIDIN-3-YLMETHYL)-1,6-NAPHTHYRIDIN-5(6H)-ONE DERIVATIVE AS C-MET INHIBITOR AMGEN INC (US) 2020-07-01 — — EP disclosed
US-20190185572-A1 COMBINATION THERAPY OF ANTIBODIES AGAINST HUMAN CSF-1R AND USES THEREOF HOFFMANN-LA ROCHE INC. (US) 2019-06-20 — — US disclosed
EP-3330292-A1 HUMAN C-FMS ANTIGEN BINDING PROTEINS Amgen, Inc (US) 2018-06-06 — — EP disclosed
US-9988457-B2 Human C-FMS antigen binding proteins AMGEN INC. (US) 2018-06-05 — — US disclosed
EP-2188313-B1 HUMAN C-FMS ANTIGEN BINDING PROTEINS AMGEN INC (US) 2017-11-01 — — EP disclosed
US-20170247459-A1 COMBINATION THERAPY OF ANTIBODIES AGAINST HUMAN CSF-1R AND USES THEREOF HOFFMANN-LA ROCHE INC. (US) 2017-08-31 — — US disclosed
EP-1648998-A2 SPECIFIC BINDING AGENTS TO HEPATOCYTE GROWTH FACTOR Amgen Inc. (US) 2006-04-26 — — EP disclosed
US-20060040966-A1 e.g. 2-(7-isoquinolinylamino)-N-(3-methyl-4-(1-methylethyl)phenyl)-3-pyridinecarboxamide; Vascular Endothelial Growth Factor antagonist; angiogenesis inhibitor; anticarcinogenic, antiinflammatory inhibitor; retinopathies, rheumatoid arthritis, asthma, atherosclerosis, endometriosis, neoplastic diseases AMGEN INC. 2006-02-23 — — US disclosed
US-20060018909-A1 Angiopoietin-2 specific binding agents AMGEN INC. 2006-01-26 — — US disclosed
US-20050118643-A1 Specific binding agents to hepatocyte growth factor AMGEN INC 2005-06-02 — — US disclosed
WO-2005017107-A2 SPECIFIC BINDING AGENTS TO HEPATOCYTE GROWTH FACTOR AMGEN INC. (US) 2005-02-24 — — WO disclosed
US-20030203922-A1 Substituted amine derivatives and methods of use AMGEN INC. 2003-10-30 — — US disclosed
US-20030195230-A1 Substituted amine derivatives and methods of use AMGEN INC. 2003-10-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060216288-A1 Combinations for the treatment of cancer TP53, VHL, FOLR2 KDR 2043/4885MAP4K4 3359/4885FLT1 1273/4885
US-20030203922-A1 Substituted amine derivatives and methods of use MAOB, HNMT, FLT4 KDR 13/4885MAP4K4 1490/4885FLT1 4/4885
US-20030195230-A1 Substituted amine derivatives and methods of use MAOB, HNMT, FLT4 KDR 13/4885MAP4K4 1490/4885FLT1 4/4885
US-20060040966-A1 e.g. 2-(7-isoquinolinylamino)-N-(3-methyl-4-(1-methylethyl)phenyl)-3-pyridinecarboxamide; Vascular Endothelial Growth Factor antagonist; angiogenesis inhibitor; anticarcinogenic, antiinflammatory inhibitor; retinopathies, rheumatoid arthritis, asthma, atherosclerosis, endometriosis, neoplastic diseases EDNRA, PTGIS, EDNRB KDR 4/4885MAP4K4 2323/4885FLT1 6/4885
US-20100074909-A1 Combinations for the treatment of cancer TP53, VHL, FOLR2 KDR 2043/4885MAP4K4 3359/4885FLT1 1273/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.